Publication:

Efficacy of intralesional immunotherapy with measles, mumps and rubella virus vaccine for the treatment of warts

Background The human papillomavirus (HPV) is the cause of warts, which are benign epithelial proliferations. Traditional therapies, such as salicylic acid and cryotherapy, frequently have poor results and a high rate of recurrence. A viable substitute is intralesional immunotherapy using the MMR vaccine, which boosts the host immune system to eradicate HPV-infected cells. The purpose of this study was to assess the intralesional MMR vaccine's effectiveness and safety in treating warts.

Methods Fifty-two patients with warts participated in a randomized clinical trial. Five intralesional MMR vaccination sessions were given to the participants at two-week intervals. At baseline and following five sessions, wart size and resolution were measured. Throughout the course of the study, adverse effects were observed.

Results After five sessions, 73.1% of patients had completely cleared their warts. There were no notable systemic side effects, and the most frequently reported adverse effect was mild erythema at the injection site.

Conclusions The intralesional MMR vaccine is a safe and efficient way to treat warts. It is less expensive than traditional treatments and has a lower chance of recurrence. To verify its long-term effectiveness, more research with bigger sample sizes and longer follow-up times is required.